Current Pharmaceutical Design
Volume 28, 46 Issues, 2022
ISSN: 1873-4286 (Online)
ISSN: 1381-6128 (Print)
This journal supports open access
ISSN: 1873-4286 (Online)
ISSN: 1381-6128 (Print)
This journal supports open access
Contents
Current Pharmaceutical Design , Volume 20 - Number 24
Editorial
Pharmacogenetics of Non-small Cell Lung Cancer (NSCLC): Time to "Work it Out"?
, 20(24): 3863 - 3874Elena Galvani, Francesca Toffalorio, Godefridus J. Peters, Tommaso De Pas and Elisa Giovannetti
DOI: 10.2174/13816128113196660756
PARP Inhibitors: An Interesting Pathway also for Non-Small Cell Lung Cancer?
, 20(24): 3875 - 3882Matteo Giaj Levra, Ken Andre Olaussen, Silvia Novello and Jean-Charles Soria
DOI: 10.2174/13816128113196660765
Signaling Pathways Modulating Dependence of Lung Cancer on Mutant Epidermal Growth Factor Receptor and Mechanisms of Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors
, 20(24): 3883 - 3893Luciano Wannesson, Santiago Viteri, Carlota Costa, Niki Karachaliou, Miguel Angel Molina-Vila and Rafael Rosell
DOI: 10.2174/13816128113196660758
Irreversible EGFR Inhibitors in the Treatment of Advanced NSCLC
, 20(24): 3894 - 3900Paolo Maione, Antonio Rossi, Marianna Bareschino, Paola Claudia Sacco, Clorinda Schettino, Francesca Casaluce, Assunta Sgambato and Cesare Gridelli
DOI: 10.2174/13816128113196660764
Combining Anti-Epidermal Growth Factor Receptor (EGFR) and Anti-Angiogenic Strategies in Advanced NSCLC: We Should have Known Better...
, 20(24): 3901 - 3913Massimo Di Maio, Alessandro Morabito, Maria Carmela Piccirillo, Gennaro Daniele, Pasqualina Giordano, Raffaele Costanzo, Claudia Sandomenico, Agnese Montanino, Gaetano Rocco and Francesco Perrone
DOI: 10.2174/13816128113196660762
MET and ALK as Targets for the Treatment of NSCLC
, 20(24): 3914 - 3932Capelletti M, Gelsomino F. and Tiseo M.
DOI: 10.2174/13816128113196660760
Across the Universe of K-Ras Mutations in Non-Small-Cell-Lung Cancer
, 20(24): 3933 - 3943Sheila Piva, Monica Ganzinelli, Marina Chiara Garassino, Elisa Caiola, Gabriella Farina, Massimo Broggini and Mirko Marabese
DOI: 10.2174/13816128113196660761
Signaling Intermediates (MAPK and PI3K) as Therapeutic Targets in NSCLC
, 20(24): 3944 - 3957Ludovica Ciuffreda, Ursula Cesta Incani, Linda S. Steelman, Stephen L. Abrams, Italia Falcone, Anais Del Curatolo, William H. Chappell, Richard A. Franklin, Sabrina Vari, Francesco Cognetti, James A. McCubrey and Michele Milella
DOI: 10.2174/13816128113196660763
Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: 'A Hard Days Night'
, 20(24): 3958 - 3972Sara Pilotto, Maria Bonomi, Francesco Massari, Michele Milella, Ludovica Ciuffreda, Matteo Brunelli, Matteo Fassan, Marco Chilosi, Aldo Scarpa, Giampaolo Tortora and Emilio Bria
DOI: 10.2174/13816128113196660757
Approaching the Increasing Complexity of Non-small Cell Lung Cancer Taxonomy
, 20(24): 3973 - 3981Marcello Maugeri-Sacca, Monica Bartucci, Alfredo Pagliuca, Michele Patrizii, Michele Signore and Ruggero De Maria
DOI: 10.2174/13816128113196660759
MicroRNAs in Non-small Cell Lung Cancer: Current Status and Future Therapeutic Promises
, 20(24): 3982 - 3990D. Cortinovis, V. Monica, F Pietrantonio, G.L. Ceresoli, C.M. La Spina and L. Wannesson
DOI: 10.2174/13816128113196660755
Editor-in-Chief
Alessandro Antonelli
(14789 citations)
Department of Clinical and Experimental Medicine
Laboratory of Primary Human Cells
University of Pisa
Pisa
(Italy)
Biography
(14789 citations)
Department of Clinical and Experimental Medicine
Laboratory of Primary Human Cells
University of Pisa
Pisa
Biography
Biography of Alessandro Antonelli
Alessandro Antonelli (Professor of Internal Medicine, MD) is Director of the Immuno-Endocrine
Section of Internal Medicine, and Head of the Laboratory of Primary Human Cells, University of
Pisa. His principal areas of expertise are autoimmune thyroid disorders, type 1 diabetes, systemic
autoimmune disorders, chemokines and cytokines, HCV-associated thyroid disorders and thyroid
cancer. His researches have been published in more than 370 articles on International journals
(Impact Factor > 1600; HI=75). He serves as an editorial board member and is Referee and
Reviewer of many scientific International journals.
Nobel Laureate on Editorial Board
Andrew V. Schally
(USA)
COPE Compliant
About the Journal
⇨ Journal Home⇨ Editorial Policies⇨ Fabricating and Stating False Information⇨ Research Misconduct⇨ Post Publication Discussions and Corrections⇨ Allegations from Whistleblowers⇨ Editorial Board⇨ Meet the Executive Guest Editor(s)⇨ Board Recruitment Workflow⇨ Short Guide⇨ Join Editorial Board⇨ Indexing Information⇨ Announcements⇨ Endorsements⇨ Authors' Comments
For Authors
For Librarians & Readers
Quick Links
Advertisement
Webmaster Contact: info@benthamscience.net